ACADEMIA

NCC Pitches Creation of New Panel to Address Info Gaps for Cancer Drugs, but Regional Hospitals Wary

July 11, 2019
The National Cancer Center (NCC) on July 10 called for a new panel to be created under a council of prefectural cooperation hospitals for cancer care to iron out regional information disparities among specialists, who now need to handle genomic…

To read the full story

ACADEMIA

By Reiji Anasako

Despite getting off to a sluggish start five years ago, SGLT2 inhibitors are steadily picking up steam thanks to buoyant sales of their combination medicines with DPP-4 inhibitors. Even monodrugs alone grew 29% in FY2018, with the market including the…

By Tatsuya Otsuka

Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…

By Yoshinori Sagehashi

With Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) hogging the headlines for its biggest-ever price tag in Japan, many continue to perceive high-price medicines as the main culprit of strained health finances, contending that they are driving up drug spending. But, is…

By Reiji Anasako

Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…

By Yoshinori Sagehashi

As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

By Yoshinori Sagehashi

Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…